New nasal spray form of bumetanide shows promise for heart failure treatment

A new nasal spray form of the medication bumetanide may reduce the tissue swelling caused by heart failure as effectively as the standard oral and intravenous formulations of the medication, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Platform Trial Looks at Endometrial Cancer Treatment Combinations

A phase II study is investigating olaparib (Lynparza), cediranib (Recentin), durvalumab (Imfinzi), or investigational capivasertib in various treatment combinations in patients with recurrent, persistent, or

July 11, 2023

Acupuncture may offer limited relief from chronic spontaneous urticaria, study finds

A randomized controlled trial that included more than 300 people diagnosed with chronic spontaneous urticaria (CSU), or hives, found that acupuncture may offer limited relief

November 14, 2023

Bolt Biotherapeutics revamps as it drops lead cancer asset, changes CEO and trims headcount

Bolt Biotherapeutics is reshuffling to cut costs and extend its cash runway to the second half of 2026. The California biotech said Tuesday afternoon that

May 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.